Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend
The $10 billion acquisition of Verona Pharma plc (NASDAQ:VRNA) by Merck & Co. (NYSE:MRK), which offered $107 per American Depositary Share, was authorized by the company’s shareholders on October 1.







